An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy within the PSA range of 2-20 μg/l;Nutzung von artifiziellen neuronalen netzwerken zur risikoabschätzung eines prostatakarzinoms: Biopsieindikationen im PSA-bereich von 2-20 μg/l

Urologe - Ausgabe A

Volumn 42, Issue 9, 2003, Pages 1221-1229

  Stephan, C ^a   Vogel, B ^a   Cammann, H ^a   Lein, M ^a   Klevecka, V ^a   Sinha, P ^a   Kristiansen, G ^a   Schnorr, D ^a   Jung, K ^a   Loening, S A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Neural network; Prostate biopsy; Prostate cancer; Prostate specific antigen; Receiver operating characteristic

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOPSY; BLOOD; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NERVE CELL NETWORK; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; MALE; MIDDLE AGED; NERVE NET; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 10744230601     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0322-7     Document Type: Article

References (18)

1. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, Zhang Z (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 μg/l. Urology 56:1000-1006
2. Carlson GD, Calvanese CB, Partiri AW (1998) An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 52:455-461
3. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 μg/l and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54:220-224
4. Catalona WJ, Partin AW, Slawin KM et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542-1547
5. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20: 921-929
6. Finne P, Finne R, Auvinen A et al. (2000) Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56:418-422
7. Jung K, Stephan C, Elgeti U et al. (2001) Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/l - are they useful tools for early detection and screening of prostate cancer? Int J Cancer 93: 759-765
8. Jung K, Stephan C, Lein M, Brux B, Sinha P, Schnorr D, Loening SA (2001) Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms-What has to be considered? Prostate 46: 307-310
9. Jung K, Stephan C, Lein M et al. (1996) Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42:1026-1033
10. Lee CT, Scardino PT (2001) Percent free Prostate-specific antigen for first-time prostate biopsy. Urology 57:594-598
11. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306
12. Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches. Cancer 91:1636-1642
13. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L (1996) Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate 7 [Suppl]: 3-16
14. Snow PB, Smith DS, Catalona WJ (1994) Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 152: 1923-1926
15. Stephan C,Jung K,Cammann H et al.(2002) An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99:466-473
16. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA (2002) Prostate specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59:2-8
17. Virtanen A, Gomari M, Kranse R, Stenman UH (1999) Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45: 987-994
18. Wymenga LF, Duisterwinkel FJ, Groenier K, Visser-van Brummen P, Marrink J, Mensink HJ (2000) Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios. Scand J Urol Nephrol 34:181-187